Insider Purchases: Inside the Buy
Tag: Nasdaq
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
TTD Stock Analysis 2026: Jeff Green’s $148M Bet — Is The Trade Desk the Ultimate “Buy the Dip” Play?
The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?
DKNG Stock Deep Dive 2026: Insider Buying, Q4 Earnings, and the “Matrix” Growth Play
DraftKings isn’t just a sportsbook anymore—it’s becoming an “internet casino layer” built on attention, probability, and habit loops. With a major insider purchase, heavy institutional ownership, improving margins, and the stock still far below its highs, DKNG may be entering its most interesting chapter yet.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.